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PROPOSITIONS ACCOMPANYING THE THESIS
Hypofractionated radiotherapy for prostate cancer: How far can we go?
1.	 Applying	 moderately	 hypofractionated	 radiotherapy	 for	 prostate	 cancer	 enhances	 the	
incidence	 of	 acute	 gastrointestinal	 toxicity,	 even	when	 only	 three	 fractions	 per	 week	 are	
delivered.	(Chapter	2)
2.	 Using	 only	 physician	 scoring	 toxicity	 reports	 after	 prostate	 cancer	 radiotherapy	 can	
substantially	underestimate	acute	and	late	toxicity.	(Chapters	2	and	3)




















STELLINGEN BEHORENDE BIJ HET PROEFSCHRIFT 
Hypogefractioneerde radiotherapie voor prostaatkanker: Hoe ver kunnen we gaan?
1.	 Het	 toepassen	 van	 gematigd	 hypogefractioneerde	 radiotherapie	 voor	 prostaatkanker	










5.	 Prostaatkanker	 patiënten	 die	 worden	 behandeld	 met	 hypogefractioneerde	 radiotherapie	
kunnen	mogelijk	geselecteerd	worden	op	basis	van	baseline	symptomen.	(Hoofdstukken	2,	
3,	7	en	9)
6.	 Toekomstige	 radiotherapie	 studies	 over	 prostaatkanker	 zouden	 meer	 aandacht	 moeten	
besteden	aan	kwaliteit	van	leven	als	eindpunt,	aangezien	dit	belangrijker	is	dan	lokale	controle.
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Article in press, Brachytherapy.
Chapter	7	–		 Toxicity	and	quality	of	life	after	high-dose-rate	brachytherapy	as	
monotherapy	for	low-	and	intermediate-risk	prostate	cancer 































Part 3 –  Extreme hypofractionation with stereotactic body radiation 
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There	 are	 several	 treatment	 options	 for	 organ-confined	 PCa.	 Next	 to	 surgery,	 external-beam	
radiotherapy	 (EBRT),	High-Dose-Rate	 (HDR)	 and	 Low-Dose-Rate	 (LDR)	 brachytherapy	 (BT),	 and	 for	
selected	 patients,	 active	 surveillance	 are	 all	 considered	 effective	 treatment	 methods.	 Choice	 of	






According	 to	 the	 linear-quadratic	 model	 for	 cell-killing,	 the	 surviving	 fraction	 of	 cells	 has	 a	
component	linear	in	delivered	dose,	αD,	and	another	component	quadratic	with	delivered	dose,	
βD2.	 For	most	 cancers,	 the	 α/β	 ratio	 is	 high	 (~10	Gy),	 indicating	 that	 these	 tissues	 are	more	
sensitive	 to	 the	 total	 radiation	dose,	 rather	 than	 the	 dose	 per	 fraction.	 For	 the	 late-reacting	












In	 the	 last	 decade,	 many	 efforts	 have	 been	 made	 to	 improve	 the	 dose	 delivery	 accuracy	 in	
EBRT,	such	as	 the	 introduction	of	 intensity-modulated	radiotherapy	 (IMRT)	and	 image-guided	












SCOPE OF THE THESIS
The	 general	 purpose	 of	 this	 thesis	was	 to	 investigate	 the	 feasibility	 of	moderate	 and	 extreme	
hypofractionated	 radiotherapy	 for	 prostate	 cancer,	 with	 emphasis	 on	 treatment	 induced	 side	
effects.	In	this	context,	in	all	clinical	studies	toxicity	was	scored	by	both	physicians	and	patients,	
using	patient	self-assessment	questionnaires	(PSAQ).	
OUTLINE OF THIS THESIS







thesis	contains	the	final	reports	on	acute	and	late	toxicity	(Chapters 2 and 3).	




boost	consisting	of	3	 fractions	of	6	Gy	for	hormone-naive	patients	with	 low-	or	 intermediate-risk	
PCa30.	Long	term	toxicity	results	were	derived	from	physicians’	reports	and	PSAQ.		




period	of	time	 (36	hours)31,35,	 the	overall	 dosimetric	 accuracy	and	 reproducibility	depended	on	 the	












Part 3: Extreme hypofractionation with SBRT using the Cyberknife
Although	HDR-BT	as	monotherapy	is	an	excellent	treatment	option	for	organ-confined	PCa,	the	
limited	 surgery	 capacity	 and	 the	 increased	 number	 of	 (older)	 patients	 with	 co-morbidities	 or	
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Hypofractionated versus conventionally 
fractionated radiotherapy for patients  
with prostate cancer (HYPRO):  
acute toxicity results from a randomised 
















Chapter 2: Acute toxicity HYPRO trial
SUMMARY
Background   
In	2007,	we	began	the	randomised	phase	3	multicentre	HYPRO	trial	 to	 investigate	the	effect	of	
hypofractionated	 radiotherapy	 compared	 with	 conventionally	 fractionated	 radiotherapy	 on	
relapse-free	 survival	 in	 patients	 with	 prostate	 cancer.	 Here,	 we	 examine	 whether	 patients	
experience	differences	in	acute	gastrointestinal	and	genitourinary	adverse	effects.
Methods   















done	 in	 the	 intention-to-treat	population.	Patient	 recruitment	has	been	completed.	This	 study	 is	
registered	with	www.controlled-trials.com,	number	ISRCTN85138529.
Findings   
Between	March	19,	2007,	and	Dec	3,	2010,	820	patients	were	 randomly	assigned	 to	 treatment	
with	standard	fractionation	(n=410)	or	hypofractionation	(n=410).	3	months	after	radiotherapy,	73	
(22%)	patients	in	the	standard	fractionation	group	and	75	(23%)	patients	in	the	hypofractionation	





2	or	worse	acute	genitourinary	 toxicity	 (57·8%	 [95%	CI	52·9–62·7]	 in	 the	standard	 fractionation	
group	 vs	 60·5%	 (55·8–65·3)	 in	 the	 hypofractionation	 group;	 difference	 2·7%,	 90%	 CI	 –2·99	 to	
8·48;	 odds	 ratio	 [OR]	 1·12,	 95%	 CI	 0·84–1·49;	 p=0·43).	 The	 cumulative	 incidence	 of	 grade	 2	 or	








Interpretation   





















Study design and participants
In	this	open-label,	randomised,	phase	3	study,	we	recruited	intermediate-risk	and	high-risk	patients13 
















We	 randomly	 assigned	 (1:1)	 patients	 to	 receive	 standard	 fractionation	 or	 hypofractionation,	









Assuming	the	α/β	ratio	was	1·5 Gy for prostate cancer,8	the	tumour	equivalent	dose	in	2	Gy	fractions	





In	 the	standard	 fractionation	group,	patients	 received	five	daily	 fractions	of	2	Gy	a	week	 (overall	
treatment	time	about	8	weeks).	Assuming	an	α/β	ratio	of	10	Gy	for	acute	toxicity,	this	would	result	in	







treated	to	a	dose	of	35	 fractions	of	2	Gy	or	39	 fractions	of	1·85	Gy	 (standard	 fractionation),	or	a	
dose	of	16	fractions	of	3·4	or	19	fractions	of	3·04	Gy	(hypofractionation	group).	For	group	3,	both	
the	prostate	and	the	seminal	vesicle	were	treated	up	to	the	prescribed	dose.	 In	the	Netherlands,	

























of	 radiotherapy	 to	59	days	after	completion	of	 radiotherapy);	and	3	months	after	 radiotherapy	
(between	60	days	till	120	days	after	completion	of	 radiotherapy).	We	also	 recorded	 incidences	
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Data	are	n	 (%)	or	median	 (IQR).	*PSA	concentration	median	 in	 the	standard	Fractionation	group	14.8	  
(IQR	9.8–24.0)	and	13.9	(9.2–21.3)	in	the	hypofractionation	group.
























86%,	 and	 for	 acute	 toxic	 effects	 71%,	 and	 so	we	 calculated	 that	we	would	 need	 to	 enroll	 820	
patients,	including	allowance	for	a	dropout	of	20	patients.	Analyses	were	intention-to-treat.	
The	 analyses	 presented	here	 are	 for	 the	 comparison	 of	 the	 cumulative	 incidences	 of	 grade	 2	 or	
worse	acute	toxic	effects;	for	each	patient,	we	included	the	highest	grade	recorded	until	120	days	
after	 completion	 of	 radiotherapy.	 Non-inferiority	 of	 hypofractionation	 was	 tested	 separately	
for	 genitourinary	 and	 gastrointestinal	 acute	 toxic	 effects,	with	 a	 null	 hypothesis	 that	 cumulative	
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n 391 403 391 402
1 115	(29%) 124	(31%) 0·45 30	(8%) 43	(11%) 0·044
≥2 85	(22%) 93	(23%) 0·65 9	(2%) 16	(4%) 0·18
2 73	(19%) 70	(17%)  - 7	(2%) 14	(3%)  -
3 12	(3%) 23	(6%) 0·068 2	(1%) 2	(<1%) 0·98 
4 - - - - - -
4 weeks
n 385 401 385 400
1 118	(31%) 120	(30%) 0·41 117	(30%) 104	(26%) 0·22
≥2 171	(44%) 191	(48%) 0·37 70	(18%) 108	(27%) 0·0031
2 131	(34%) 144	(36%) - 62	(16%) 97	(24%)  -
3 40	(10%) 45	(11%) 0·55 8	(2%) 11	(3%)  0·54
4 - 2	(<1%) - - - -
6 weeks
n 376 376 378 376
1 100	(27%) 98	(26%) 0·46 98	(26%) 81	(22%) 0·27
≥2 178	(47%) 171	(45%) 0·61 86	(23%) 117	(31%) 0·01
2 144	(38%) 125	(33%) - 72	(19%) 104	(28%)  -
3 33	(9%) 45	(12%) 0·16 14	(4%) 13	(3%) 0·86
4 1	(<1%) 1	(<1%) - - - -
3	month	after	radiotherapy
n 325 327 326 327
1 56	(17%) 91	(28%) 0·0045 47	(14%) 56	(17%) 0·51
≥2 73	(22%) 75	(23%) 0·89 43	(13%) 42	(13%) 0·90
2 47	(14%) 51	(16%) - 39	(12%) 32	(10%)  -
3 25	(8%) 23	(7) 0·75 4	(1%) 10	(3%) 0·11 
4 1	(<1%) 1	(<1%) - - - -
Maximum	toxicity	score	after	radiotherapy
n 391 403 391 402
1 114	(29%) 120	(30%) 0·14 140	(36%) 129	(32%) 0·028
≥2 226	(58%) 244	(61%) 0·43 122	(31%) 169	(42%) 0·0015
2 155	(40%) 160	(40%)  104	(27%) 146	(36%)  
3 69	(18%) 82	(20%) 0·34 18	(5%) 23	(6%) 0·48 







Gleason	 score,	 T	 stage,	 previous	 transurethral	 prostate	 resection,	 use	 of	 hormonal	 therapy,	





According	 to	 the	 protocol,	 Cox	 regression	 modelling	 was	 used	 for	 late	 toxic	 effects	
but	 not	 for	 acute	 toxic	 effects.	 No	 corrections	 for	 multiple	 testing	 were	 applied	 and	 all	
reported	 p	 values	 were	 based	 on	 two-sided	 tests.	 We	 deemed	 a	 p	 value	 of	 less	 than	 0·05 
as	 significant.	 Analyses	 were	 done	 with	 STATA	 (version	 13.1).	 This	 study	 is	 registered	 with	 
www.controlled-trials.com,	number	ISRCTN85138529.
Figure 2.2 | Acute	toxicity	as	a	function	of	time
Cumulative	 incidence	 of	 grade	 2	 or	worse	 genitourinary	 toxic	 events	 (A),	 prevalence	 of	 grade	 2	 or	worse	
genitourinary	toxic	events	(B),	and	distribution	of	genitourinary	toxicity	scores	(C).	Cumulative	incidence	of	
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Role of the funding source
The funder provided peer-reviewed approval for the trial, but had no other role in study design, 








being	treated	or	they	died	before	start	of	 treatment	 (n=10),	or	non-evaluability	 for	acute	toxicity	
(n=1),	resulting	in	794	assessable	patients	(391	in	the	standard	fractionation	group	and	403	in	the	
hypofractionation	group;	figure	1).	 Table	1	 shows	baseline	 characteristics.	 There	were	 treatment	 
delivery	 deviations	 in	 14	 patients	 (six	 in	 the	 standard	 fractionation	 group,	 eight	 in	 the	 
Table 2.3 | Specific	symptoms	according	to	treatment	group






Pain	needing	drugs	(grade	2) 14	(4%) 21	(5%) 0·26
Macroscopic	haematuria	(grade	3) 9	(2%) 15	(4%) 0·24




Increased frequency at night 
>seven	times	(grade	3)
26	(7%) 46/401	(12%)* 0·019
Incontinence	(grade	3) 39/364	(11%)* 49/372	(13%)* 0·30
Gastrointestinal
Pain	needing	drugs	(grade	2) 18	(5%) 35	(9%) 0·021
Diarrhoea	with	drugs	(grade	2) 19	(5%) 21	(5%) 0·82
Increased	frequency	≥	six	(grade	2) 31	(8%) 58	(15%) 0·0035
Use	of	pads	(grade	3) 22	(6%) 32	(8%) 0·19







hypofractionation	 group)	 that	 included	 temporary	 interruption	 for	 three	 patients	 (two	 in	 the	
standard	 fractionation	 group,	 one	 in	 the	 hypofractionation	 group),	 discontinuation	 of	 irradiation	
in	 three	 patients	 because	 of	 toxic	 effects	 (one	 in	 the	 standard	 fractionation	 group,	 two	 in	 the	




modulated	 radiation	 therapy	and	 set-up	 verification	and	 correction	based	on	 implanted	fiducials	
were	used	 in	 370	 (95%)	of	 391	patients	 in	 the	 standard	 fractionation	group	and	 in	 380	 (94%)	of	
403	patients	in	the	hyprofractionation	group.	Median	time	from	onset	of	hormonal	therapy	to	the	
date	of	planning	CT	or	MRI	was	1·7	months	(IQR	0·8–2·8)	in	the	standard	fractionation	group	and	
1·8	months	 (0·9–3·3)	 in	 the	hyprofractionation	group.	At	closure	of	 the	database	 (Sept	12,	2014),	
716	patients	 (354	 in	standard	fractionation	group	and	362	 in	hyprofractionation	group)	were	still	
alive	with	a	median	follow	up	of	49·2	months	(IQR	9·2–58·2).	We	noted	no	significant	difference	in	
cumulative	 incidence	up	 to	120	days	after	 radiotherapy	of	 grade	2	or	worse	acute	genitourinary	
toxicity	(57·8%	[95%	CI	52·9–62·7]	in	the	standard	fractionation	group	vs 60·5%	[55·8–65·3]	in	the	
hypofractionation	group;	difference	2·7%,	90%	CI	–2·99 to 8·48;	OR	1·12,	95%	CI	0·84–1·49;	p=0·43; 
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15·7(8·4-29·5) <0·001 14·5(7·7-27·3) <0·001
Age	(>70	years) 1·45(1·09-1·92) 0·011 1·38(1·00-1·90) 0·051
PSA	(<20) 0·90(0·66-1·22) 0·49 -
Gleason(<7) 0·68(0·49-0·96) 0·026 -  
T-stage(T3-T4	vs	T1-T2) 1·24(0·93-1·64) 0·14 -  
Transurethral	prostate	resection 0·86(0·53-1·38) 0·53 0·88(0·52-1·49) 0·63
Adjuvant	hormonal	therapy 1·11(0·82-1·50) 0·49 -
Months	hormonal	therapy	before	RT
 <2 vs none












Abdominal	surgery 1·19(0·86-1·65) 0·30   
Gastrointestinal	comorbidity 1·03(	0·64-1·66) 0·92 0·97(0·57-1·65) 0·90























5·8(2·3-14·6) <0·0001 5·5(2·1-14·3) 0·0010
Age	(>70	years) 1·23(0·92-1·64) 0·17 1·23(0·91-1·68) 0·18
PSA	(<20) 0·86(0·63-1·18) 0·35 -
Gleason	(<7) 0·84(0·60-1·17) 0·29 -
T	stage	(T3-T4	vs	T1-T2) 0·98(0·74-1·31) 0·90 -
Transurethral	prostate	resection 0·81(0·49-1·34) 0·41 0·75(0·45-1·27) 0·29
Adjuvant	hormonal	therapy 0·74(0·55-1·00) 0·052 -
Months	of	hormonal	therapy	
before radiotherapy
 <2 vs none



















Abdominal	surgery 0·93(0·66-1·29) 0·65  1·0
GI	comorbidity 1·25(0·78-2·02) 0·36 1·24(0·74-2·06) 0·41
prostate	volume	(>50	vs	<50	cm3) 1·49(1·11-2·00) 0·008 1·33(0·97-1·82) 0·079
Treatment	group	
 2 vs 1
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RESEARCH IN CONTEXT 
Systematic review  
We	 searched	 Medline	 without	 language	
restriction	 between	 February,	 2005,	 and	
May,	2006,	with	the	search	terms	“prostate	
cancer”,	“radiotherapy”,	“hypofractionation”,	
“alpha	 beta	 ratio”,	 “toxicity”.6–8,10–12,21 The 
scientific	 literature	 shows	 evidence	 for	 a	
low	 α/β	 ratio	 for	 prostate	 cancer6–8 with a 
potential	for	an	enhanced	therapeutic	ratio	
for	 hypofractionated	 radiotherapy.	 In	 the	
development	phase	of	the	HYPRO	trial,	only	
a	 few,	 small	 randomised	 hypofractionation	
trials had been published,10–12 which 
were	 mostly	 done	 with	 lower	 treatment	
doses	 (66–72	 Gy).	 The	 use	 of	 intensity-
modulated	 radiation	 therapy	 and	 image-
guided radiotherapy are associated with low 
toxicity	 rates.22–25 The availability of these 
techniques	 to	 prevent	 excessive	 toxicity	
favoured	 launching	 of	 a	 hypofractionation	
trial.	 The	 aim	 of	 the	 HYPRO	 trial	 is	 to	
show superior relapse-free survival for 
hypofractionation	 compared	with	 standard	
fractionation,	with	non-inferiority	for	toxicity,	
prescribing	 an	 enhanced	 tumour	 EQD2Gy.	 
To our knowledge, only one other trial 
aimed	at	relapse-free	survival	enhancement	
with	hypofractionation	with	a	small	patient	
sample,26 whereas other trials11,27 addressed 
toxicity	 or	 non-inferiority	 by	 use	 of	 a	 low	
tumour	EQD2Gy.
Interpretation  
Hypofractionation	 was	 not	 non-inferior	
to	 standard	 fractionation	 for	 acute	
genitourinary	 and	 gastrointestinal	 toxicity;	
indeed,	the	cumulative	incidence	of	grade	2	
or	worse	acute	gastrointestinal	toxicity	was	
significantly	 higher	 for	 hypofractionation.	
However,	 by	 3	months	 after	 completion	of	
radiotherapy,	 differences	 in	 genitourinary	
and	 gastrointestinal	 toxicities	 were	 not	
significant.	 Presence	of	 baseline	 symptoms	
was	 the	 most	 important	 predictive	 factor	
for	acute	 toxicity.	The	use	of	patients’	 self-
assessment	 questionnaires	 complementary	
to	 case	 report	 forms	 can	 prevent	 serious	
under-reporting	 of	 toxic	 effects	 and	 is	
recommended.	These	finding	are	useful	for	









when	 adjusting	 for	 all	 those	 factors,	 hypofractionation	 remained	 associated	 with	 a	 significantly	
higher	cumulative	incidence	of	grade	2	or	worse	acute	gastrointestinal	toxicity	than	with	standard	
fractionation	(OR	1·57, CI 1·16–2·13;	p=0·0034).	
For	both	genitourinary	and	gastrointestinal	adverse	events,	 the	total	 reported	 incidences	derived	
from	 the	 combined	 use	 of	 case	 report	 form	 and	 patients’	 self-assessment	 questionnaires	 were	
substantially	higher	than	for	case	report	form	only	(figure	3).
DISCUSSION














Several	 investigators	 have	 reported	 increased	 acute	 toxicity	 with	 hypofractionation.	 In	 these	
studies,	the	overall	treatment	time	was	shorter	for	the	hypofractionation	group	than	the	standard	




















fractionated	 radiotherapy;	 for	 hypofractionation	 there	was	 a	 peak	 at	 4–5	weeks	 (the	 duration	
of	 the	hypofractionation	course	was	4	weeks).	 Investigators	of	 the	CKVO	96-10	 trial29 reported 

















Often,	acute	toxicity	scoring	 is	based	on	case	report	 forms	only.	 In	our	 trial,	 scoring	was	based	
on	both	case	report	forms	and	patients’	self-assessment	questionnaires.	The	addition	of	patients’	
self-assessment	questionnaires	 to	 the	analyses	 resulted	 in	 significant	 increases	 in	 the	 reported	
incidence	 of	 acute	 toxicity	 (figure	 3).	 Underestimation	 of	 toxicity	 by	 use	 of	 case	 report	 forms	
has	 been	 reported	 previously.30	 Addition	 of	 patients’	 self-assessment	 questionnaires	 results	
in	more	 robust	 toxicity	 scores	 and	might	 seriously	 affect	 conclusions	 drawn	 from	 studies.	 The	
means	of	toxicity	scoring	should	be	accurately	described	to	allow	comparison	with	other	studies.	
Preferentially,	both	case	report	form	and	patients’	self-assessment	questionnaires	should	be	used.	


















was	 about	 23%	 in	 both	 groups,	 which	 is	 the	 same	 as	 the	 baseline	 level.	 This	 finding	 suggests	
that	most	acute	genitourinary	 symptoms	were	 reversible	 in	both	groups	within	3	months	after	
radiotherapy.	Presence	of	baseline	grade	2	or	worse	gastrointestinal	or	genitourinary	symptoms	
was	 strongly	 associated	 with	 enhanced	 incidence	 of	 acute	 gastrointestinal	 and	 genitourinary	




In	 conclusion,	 hypofractionated	 radiotherapy	 for	men	with	 prostate	 cancer	 is	 not	 non-inferior	
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SUMMARY 
Background  




of	 genitourinary	 and	 gastrointestinal	 toxicity;	 here	we	 report	 data	 for	 late	 genitourinary	 and	
gastrointestinal	toxicity.	
Methods
In	 this	 randomised	 non-inferiority	 phase	 3	 trial,	 done	 in	 seven	 radiotherapy	 centres	 in	 the	
Netherlands,	we	enrolled	intermediate-risk	or	high-risk	patients	aged	between	44	and	85	years	
with	 histologically	 confirmed	 stage	 T1b–T4	Nx–0	Mx–0	 prostate	 cancer,	 a	 prostate-specific	
antigen	concentration	of	60	ng/mL	or	lower,	and	WHO	performance	status	of	0–2.	A	web-based	
application	was	used	to	randomly	assign	(1:1)	patients	to	receive	either	standard	fractionation	





grade	2	or	worse	 acute	 and	 late	 genitourinary	 and	 gastrointestinal	 toxicity.	We	planned	 to	
reject	 inferiority	of	hypofractionation	for	 late	genitourinary	 toxicity	 if	 the	estimated	hazard	







Between	March	19,	2007,	and	Dec	3,	2010,	820	patients	 (410	 in	both	groups)	were	 randomly	
assigned.	Analyses	for	late	toxicity	included	387	assessable	patients	in	the	standard	fractionation	
group	and	395	in	the	hypofractionation	group.	The	median	follow-up	was	60	months	(IQR	51·2–
67·3).	 The	database	 for	 all	 analyses	 (both	groups	and	both	genitourinary	and	gastrointestinal	










RESEARCH IN CONTEXT 
Evidence before this study 
When	 the	 HYPRO	 trial	 was	 being	 planned	
and	developed,	only	a	few,	small	randomised	
hypofractionation	trials	had	been	published,	
which	 were	 done	 mostly	 with	 lower	
treatment	 doses	 (66–72	 Gy).	 Scientific	
literature	showed	 initial	evidence	for	a	 low	
α	 to	ß	 ratio	 for	prostate	cancer.	There	was	
a	 clear	 need	 for	 large	 randomised	 trials	 to	
test	 the	 predicted	 enhanced	 therapeutic	
ratio	 with	 hypofractionation.	 The	 use	 of	
intensity-modulated	 radiotherapy	 and	
image-guided	 radiation	 therapy	with	 lower	
published	 toxicity	 had	 become	 common.	
Availability of these techniques to prevent 
excessive	 toxicity	 favoured	 launching	 of	 a	
hypofractionation	 trial.	 The	 HYPRO	 trial	
aimed	to	show	superior	relapse-free	survival	
with	 hypofractionation,	 by	 prescribing	 an	
enhanced	 tumour	 equivalent	 dose	 in	 2	Gy	
fractions	 (EQD2Gy)	 compared	with	 standard	
fractionation,	without	increasing	toxicity.	To	
our	 knowledge,	only	one	other	 trial	 aimed	
at	 relapse-free	 survival	 enhancement	 with	
hypofractionation	 with	 a	 small	 patient	
sample,	 whereas	 other	 trials	 addressed	
toxicity	 or	 non-inferiority,	 using	 a	 lower	
tumour	EQD2Gy.	
Added value of this study 
Our	 findings	 could	 not	 confirm	 the	 per-
protocol hypothesized non-inferiority of 
hypofractionation	 for	 late	 genitourinary	
and	 gastrointestinal	 toxicity.	Moreover,	 the	
cumulative	 incidence	 of	 grade	 3	 or	 worse	
late	 genitourinary	 toxicity	 was	 significantly	
higher	 in	 the	 hypofractionation	 group.	
Because the hypothesized non-inferiority 
of	 hypofractionation	 for	 late	 toxicity	 was	
based	 on	 calculations	 with	 the	 linear-
quadratic	model	with	the	generally	applied	
α	 to	β	 ratio	of	4–6	Gy	 for	 late	 toxicity,	 this	
approach	might	be	questionable.	The	use	of	
patient	 self-assessment	 questionnaires	 on	
top	of	clinical	record	forms	did	significantly	
enhance	reported	late	toxicity.
Implication of all available evidence
Together	 with	 previous	 findings	 that	
were unable to show non-inferiority 
of	 hypofractionation	 for	 both	 acute	
gastrointestinal	 and	 genitourinary	 toxicity,	
and	 the	 recorded	 significant	 increase	 in	
incidence	 of	 acute	 gastrointestinal	 toxicity,	
the	 findings	 of	 late	 toxicity	 question	 the 
added	 value	 of	 hypofractionation	 with	
a	 fraction	 dose	 higher	 than	 3	 Gy	 for	
all	 patients,	 and	 the	 need	 for	 patient	
selection—eg,	based	on	baseline	symptoms,	
which can reduce both genitourinary 
and	 gastrointestinal	 toxicity.	 Before	
conclusions	 can	 be	 made	 about	 the	 value	
of	 hypofractionation,	 treatment	 outcomes	
need	 to	 be	 reported.	 The	 addition	 of	
patient	 self-assessment	 questionnaires	
to	 toxicity	 reporting	 with	 clinical	 record	
forms	 could	 avoid	 serious	 toxicity	 under-
reporting.	 The	 findings	 of	 reported	
genitourinary	 and	 gastrointestinal	 toxicity	
on	 the	 application	 of	 the	 linear-quadratic	
model	 should	 be	 considered	 in	 the	 design	
of	 new	 hypofractionation	 trials.	 Whether	
hypofractionation	can	be	incorporated	in	to	
routine	clinical	practice	will	depend	on	the	
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With	an	estimated	HR	of	1·19	 (90%	CI	0·93–1·52)	 for	 the	 cumulative	 incidence	of	 grade	2	or	
worse	late	gastrointestinal	toxicity,	we	could	not	confirm	non-inferiority	of	hypofractionation	
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toxicity,7,8	 the	EQD2Gy	 for	19	×	3·4	Gy	would	be	77·5–79·7	Gy,	 close	 to	 the	78	Gy	 for	 standard	
fractionation.	 Therefore,	 we	 expected	 incidences	 of	 late	 genitourinary	 and	 gastrointestinal	
toxicities	 to	 be	 similar	 to	 late	 genitourinary	 and	 gastrointestinal	 toxicity	 in	 standard	 group.	
We	chose	three	fractions	per	week	 for	hypofractionation	to	make	the	overall	 treatment	time	
















(stage	 T1b–T2a,	 Gleason	 score	 ≤6,	 prostate-specific	 antigen	 ≤10	 ng/mL).9,10	 Each	 participating	
centre	followed	its	own	protocol	for	adjuvant	hormonal	therapy,	which	had	to	be	applied	equally	
for	both	study	groups.	This	trial	was	approved	by	the	medical	ethics	committee	of	the	Erasmus	
Medical	Centre	 in	Rotterdam,	the	Netherlands	 (06-045).	All	patients	provided	written	 informed	
consent.	The	trial	was	coordinated	and	managed	by	the	Department	of	Radiation	Oncology	and	the	
Clinical	Trials	Center	of	the	Erasmus	MC	Cancer	Institute.	
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Depending	on	the	set-up	verification	and	correction	strategy	used	in	each	participating	institute,	
margins	 of	 3–10	mm	were	 added	 to	 the	 clinical	 target	 volume	 (equal	 in	 both	 groups),	 yielding	






form,	 as	 reported	by	 the	 treating	physician,	 following	 the	Radiation	Therapy	Oncology	Group-
























dose	escalation	study10)	 to	20%	 in	relapse-free	survival	 (the	primary	endpoint)	with	a	power	of	
92%	for	800	patients.	Non-inferiority	for	late	toxicity	was	tested	separately	for	late	genitourinary	
and	 gastrointestinal	 toxicities,	 with	 the	 null	 hypothesis	 that	 the	 cumulative	 incidence	 in	 the	
hypofractionation	group	was	8%	or	higher	than	in	the	other	group	against	the	alternative	hypothesis	





















transurethral	 resection	 of	 the	 prostate	 (TURP),	 use	 of	 hormonal	 therapy,	 previous	 abdominal	
morbidity	and	surgery,	prostate	volume,	 treatment	group	according	 to	 risk	of	 seminal	vesicle	
involvement,	and	treatment	group	on	late	toxicity	incidence.	Hazard	ratios	(HRs)	with	95%	CIs	














This	 trial	 was	 approved	 by	 the	 medical	 ethics	 committee	 of	 the	 Erasmus	Medical	 Center	 in	
Rotterdam,	 the	Netherlands	 (06-045),	and	 registered	with	www.controlledtrials.com,	number	
ISRCTN85138529.	
Role of the funding source 
The funder provided peer-reviewed approval for the trial, but had no other role in study design, 
collection,	 analyses	 or	 interpretation	 of	 data.	 The	 corresponding	 author	 and	 the	 principal	
investigators	of	the	study	(LI	and	FP)	had	full	access	to	all	data	and	had	final	responsibility	for	the	
decision	to	submit	for	publication.	


























































































































Chapter 3: Late toxicity HYPRO trial
RESULTS 
Between	March	19,	2007,	and	Dec	3,	2010,	820	patients	from	seven	Dutch	centres	were	randomly	
assigned	 to	 treatment	with	 standard	 fractionation	 (n=410)	 or	 hypofractionation	 (n=410).	 Patient	





















comparison	of	 the	Kaplan-Meier	estimates	of	cumulative	 late	genitourinary	toxicity	 incidence	
for	 standard	 fractionation	 and	 hypofractionation.	 The	 cumulative	 incidence	 of	 grade	 3	 or	
worse	late	genitourinary	toxicity	was	significantly	higher	in	the	hypofractionation	group	(19·0%	




















Chapter 3: Late toxicity HYPRO trial
Table	 2	 presents	 specific	 symptoms	 of	 late	 genitourinary	 and	 gastrointestinal	 toxicity	 in	 the	
hypofractionation	 and	 standard	 fractionation	 groups.	 Incidences	 of	 nocturia	 (≥6	 times	 per	
night;	OR	4·94,	95%	CI	1·87–13·09;	p=0·0005)	and	incontinence	(1·52;	1·03–2·24;	p=0·04)	were	
significantly	 higher	 in	 the	 hypofractionation	 group	 than	 in	 the	 standard	 fractionation	 group.	
Stool	frequency	of	more	than	six	per	day	was	significantly	increased	with	hypofractionation	(7%)	
compared	with	standard	fractionation	(3%;	OR	2·11,	95%	CI	1·07–4·15;	p=0·034;	table	2).	
Table	 3	 presents	 the	 results	 of	 the	 univariate	 and	 multivariate	 Cox	 proportional	 hazards	 








p<0·0001)	 and	 treatment	 group	 3	 (seminal	 vesicles	 treated	 to	 the	 prescribed	 dose)	 versus	 1	
(=10%	risk	of	seminal	vesicle	involvement;	1·65,	1·02–2·67;	p=0·042)	were	significantly	associated	
with	 increased	cumulative	 incidence	of	grade	2	or	worse	 late	gastrointestinal	toxicity.	Table	4	
shows	all	 symptoms	 that	are	 significantly	 associated	with	prognostic	 factors	 identified	 in	 the	
multivariate	analyses	for	both	late	genitourinary	and	gastrointestinal	toxicity.	










fractionation	 vs	 122	 [31%]	 in	 hypofractionation),	 this	 toxic	 effect	 was	 reported	 in	 the	 clinical	
















OR (95% CI) p-value*
Late genitourinary toxicity








9	(2%) 12	(3%) 1·32	(0·55–3·16) 0·66
Frequency	at	day	≥16	
urination/voiding
30	(8%) 40	(10%) 1·34	(0·82–2·20) 0·26
Frequency	at	day	≥	32	
urination/voiding
5	(1%) 8	(2%) 1·58	(0·51–4·87) 0·58
Frequency	at	night	4-6	
urination/voiding
75	(19%) 92	(23%) 1·26	(0·90–1·78) 0·19
Frequency	at	night	≥6	
urination/voiding
5	9	(1%) 24	(6%) 4·94	(1·87–13·09) <0·0005
Incontinency 52	(14%) 75	(20%) 1·52	(1·03–2·23) 0·04
 Late gastrointestinal toxicity
Drugs for pain 31	(8%) 32	(8%) 1·01	(0·60–1·69) 1·00
Drugs for diarrhoea 9	(2%) 6	(2%) 0·65	(0·23–1·84) 0·44
Frequency	≥	6 13	(3%) 27	(7%) 2·11	(1·07–4·15) 0·034
Use	of	pads 45	(12%) 63	(16%) 1·44	(0·96–2·18) 0·097




9	(2%) 18	(5%) 2·01	(0·89–4·52) 0·11
 
					*p	values	are	based	on	Fisher’s	exact	test.
Table 3.2 | Specific	symptoms	according	to	treatment	group
assessable	patients	(82	[21%]	given	standard	fractionation	vs	96	[24%]	given	hypofractionation),	
a	cumulative	incidence	of	grade	2	or	worse	late	gastrointestinal	toxicity	was	registered	in	clinical	
record	 form,	patients’	 self-assessment	questionnaires,	or	both.	For	141	 (18%)	of	 these	patients	
(64	 [17%]	standard	 fractionation	vs	77	 [20%]	hypofractionation),	 these	 toxicities	were	reported	
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Table 3.3 | Univariate	 and	 multivariate	 Cox	 proportional	 hazards	 regression	 analyses	 exploring	 the	
association	of	baseline	and	treatment-related	factors	with	the	recorded	cumulative	incidence	of	grade	2	or	
worse	late	gastrointestinal	and	genitourinary	toxicity
 Univariate*  Multivariate







2·57(2·03-3·25) <0·001 2·51(1·98-3·17) <0·0001



















 2 vs 1




















2·77(1·06-3·74) <0·001 2·75(2·02-3·	73) <0·0001























 2 vs 1


























The	 results	 of	 our	 randomised,	 phase	 3	 trial	 comparing	 hypofractionation	 with	 standard	
fractionation	 for	 patients	 with	 intermediate-risk	 and	 high-risk	 prostate	 cancer	 showed	 that	










Chapter 3: Late toxicity HYPRO trial
Figure 3.3 | Forest	plots	of	hypofractionation	compared	to	standard	fractionation	for	grade	2	or	worse	late	
toxicities	for	(A)	genitourinary	and	(B)	gastrointestinal	in	prognostic	subgroups
HR=hazard	 ratio.	 GU=genitourinary.	 PSA=prostate-specific	 antigen.	 TURP=transurethral	 resection	 of	






In	 the	 HYPRO	 trial,	 the	 recorded	 5-year	 cumulative	 incidence	 of	 grade	 2	 or	 worse	 late	 
genitourinary	 toxicity	 was	 46%,	 which	 is	 higher	 than	 the	 5-year	 to	 7-year	 late	 genitourinary	
toxicity	reported	in	other	studies	using	a	conventional	three-dimensional	treatment	technique.12 
The	 effect	 of	 intensity	 modulated	 radiotherapy	 and	 image	 guidance	 (as	 applied	 for	 most	 




Hormonal	 therapy	 was	 reported	 as	 significantly	 associated	 with	 higher	 incidences	 of	 late	
genitourinary	toxicity,12 which	was	confirmed	here.	66%	of	our	patients	had	hormonal	therapy,	
which	 could	 partly	 explain	 the	 higher	 late	 genitourinary	 toxicity	 incidence	 for	 standard	





195	 in	 the	 hypofractionation	 group)	 could	 also	 have	 contributed	 to	 the	 increased	 incidence	 of	













  Drugs for pain 4·76	(2·69–8·41) <0·0001
		Incontinence 2·55	(1·69–3·85) <0·0001
Treatment	group	(3	vs	2,	2	vs	1)
  Drugs for diarrhoea 2·23	(0·99–5·04) 0·042
	*OR=odds	ratio.



















toxicity	 for	 hypofractionation	 (p=0·073),	 but	 the	 recorded	 cumulative	 incidence	 of	 grade	 3	 late	
genitourinary	toxicity	was	significantly	higher	 in	the	hypofractionation	group	(p=0·021).	 Incidence	
of	 grade	3	night	 frequency	of	 voiding	or	urination	 (≥six	per	night)	was	 significantly	higher	 in	 the	
hypofractionation	 group	 than	 the	 standard	 fractionation	 group	 (6%	 vs	 1%,	 respectively).	 This	









modulated	 radiotherapy	 (95%)	 in	 the	 HYPRO	 trial,	 compared	 with	 12%	 in	 the	 CKTO	 study,	 the	
frequent	 use	 of	 implanted	 fiducials	 and	 daily	 set-up	 verification	 and	 correction,	 and	 the	 more	
















The	 reported	 incidences	 of	 grade	 2	 or	 worse	 late	 genitourinary	 and	 gastrointestinal	 toxicity	





Recently,	 the	2-year	patient-reported	outcomes	 for	2100	patients	 included	 in	 the	CHHiP	 trial	
were published,23	reporting	no	differences	in	quality	of	life	between	the	applied	standard	and	
hypofractionated	 regimens.	 The	questionnaires	applied	 in	 the	CHHiP	 trial	were	quality-of-life	
measurement	instruments,	in	contrast	to	the	patients’	self-assessment	questionnaires	used	in	













Symptom	 Score	 (IPSS)	 as	 correlated	 with	 higher	 incidence	 of	 late	 genitourinary	 toxicity	 (HR	
2·54).	The	IPSS	was	not	used	in	the	HYPRO	trial,	but	we	found	a	clear	correlation	between	late	
genitourinary	toxicity	and	the	presence	of	baseline	symptoms	equivalent	to	grade	2	or	worse	









































For	 both	 acute6	 and	 late	 genitourinary	 and	 gastrointestinal	 toxicity,	 non-inferiority	 of	
hypofractionation	could	not	be	confirmed.	Moreover,	the	cumulative	incidence	of	grade	3	or	worse	
late	genitourinary	toxicity	was	significantly	higher	in	the	hypofractionation	group	than	for	standard	







Toxicity	 data	 are	 not	 sufficient	 to	 influence	 routine	 clinical	 implementation	 of	 the	 tested	
hypofractionation	schedule;	the	efficacy	data	are	also	needed	before	such	adjustments	can	be	made.	














SA	 recruited	patients,	 collected,	analysed,	and	 interpreted	data,	 and	wrote	 the	 report;	 LI	 and	FP	
were	the	primary	 investigators	 involved	 in	study	design,	recruited	patients,	 interpreted	data,	and	
reviewed	the	report;	ES,	SK,	PPvT,	and	HdJ	contributed	to	protocol	development,	recruited	patients,	
and	reviewed	the	report;	WH	interpreted	data	and	reviewed	the	report;	WGA	did	statistical	analyses,	
interpreted data, and reviewed the report; and BH developed the protocol, interpreted data and 
wrote	the	report.	
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Extreme hypofractionation  









High-Dose-Rate (HDR) Brachytherapy and 
External Beam Radiotherapy (EBRT) for 
hormone-naïve low and intermediate risk 






































in	 264	 prostate	 cancer	 patients	 treated	
with	external-beam	radiotherapy	and	HDR-




Phoenix	 definition.	 Local	 recurrence	 in	 1	
patient	and	clinical	progression	in	2	patients.	
Freedom	from	biochemical	failure	was	97%.	








prostate	 cancer	 (PC).	 High	 doses	 >70	Gy	 have	 to	 be	 used	 to	 achieve	 a	 good	 local	 control,	 but	


























































































morbidity	 scales,	 using	 a	 combination	 of	 the	 patient	 EORTC-RTOG	 questionnaire	 information,	
and	the	RTOG	scores	from	the	physicians	notes	and	patient	charts.	Toxicities	within	90	days	after	









































rectal	bleeding	 (1.5%);	all	4	were	 treated	after	 the	first	year	 following	HDR-BT.	For	 the	GU	 late	
toxicity	 registered	with	 the	RTOG-score,	 the	percentage	of	patients	with	grade	2	 toxicities	was	
6.3%	at	6	months,	and	remained	at	an	average	of	10%	afterwards.	Late	grade	3	GU	toxicities	were	




PSA Nadir and Bounce:
The	 PSA	 Nadir	 of	 the	 BF-free	 patients	 was	 reached	 after	 a	mean	 of	 43.5	months	 (range,	 5.5-
122.1	months)	with	a	mean	value	of	0.32	ng/ml	(range,	0.0-4.3	ng/ml).	A	Nadir	≤	1	was	reached	
after	a	mean	of	44.9	months	 (range,	5.5-122.0	months)	 in	95.0%	whilst	 in	4.9%	of	 the	patients	
the	Nadir	>	1	was	reached	 in	17.9	months	(range,	5.7-40.2	months).	Three	patients	had	a	Nadir	























High-dose-rate	 brachytherapy	 in	 combination	 with	 EBRT	 was	 given	 for	 localized	 low-	 and	
intermediate-risk	 PC.	 This	 group	 of	 patients	 can	 be	 treated	 with	 radical	 prostatectomy	 with	
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Figure 4.2. | Radiation	Therapy	Oncology	Group	gastrourinary	(GU)	≥	grade	2	toxicity	(%).





Oncological outcome:  













radical	 prostatectomy	 with	 an	 undetectable	 PSA	 afterwards.	 Two	 patients	 with	 proven	 bone	
metastases	started	HT	and	the	other	5	patients	with	BF	are	conservatively	followed	with	a	yearly	




























Acute and late toxicities:
Compared	with	the	results	from	literature,	we	report	a	very	acceptable	and	low	rate	of	grade	≥	2	
GU	and	GI	toxicities.	Martinez	et	al.	2	reported	a	5-year	actuarial	rate	for	grade	3	and	4	toxicities	
of	8%	and	0%	for	GU	toxicities	and	0.5%	and	0.5%	for	GI	toxicities,	respectively.	Galalae	et al. 3 
reported	2%	in	terms	of	cystitis	and	4.1%	proctitis	and	6%	incontinence.	Sato	et al. 4 reported a very 
low	grade	2	GU	and	GI	toxicities	of	0%	and	3.8%,	respectively.
Demanes	et	al.18	report	results	with	long	FU	of	6.7%	and	1%	for	grade	3	and	4	for	late	GU	toxicities	
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HDR monotherapy for prostate cancer:  
A simulation study of catheter  
displacement on target coverage  








Chapter 5: Implant displacement in HDR prostate monotherapy
ABSTRACT
Purpose:
The	 aim	 of	 this	 study	was	 to	 systematically	 analyse	 the	 effect	 of	 catheter	 displacements	 both	
on	 target	 coverage	and	normal	tissue	 irradiation	 in	 fractionated	high	dose	 rate	 (HDR)	prostate	
brachytherapy,	 using	 a	 simulation	 study,	 and	 to	 define	 tolerances	 for	 catheter	 displacement	
ensuring	that	both	target	coverage	and	normal	tissue	doses	remain	clinically	acceptable.	Besides	
the	effect	of	 total	 implant	displacement,	also	displacements	of	 catheters	belonging	 to	selected	
template	rows	only	were	evaluated	in	terms	of	target	coverage	and	normal	tissue	dose,	in	order	
to	analyse	 the	 change	 in	dose	distribution	as	a	 function	of	 catheter	dwell	weight	and	catheter	
location.	
Material and methods:
Five	 representative	 implant	 geometries,	 with	 17	 catheters	 each,	 were	 selected.	 The	 clinical	





















or	 as	monotherapy	 for	 early	 stage	 prostate	 cancer	 patients	 is	 increasing	 worldwide	 1-6.	 General	
recommendations	 on	 how	 to	 perform	 HDR	 temporary	 brachytherapy	 for	 prostate	 cancer	 can	
















relative	to	 implanted	markers	using	a	set-up	protocol.	The	position	of	the	catheters	 is	adjusted	 if	















































a	 displacement	 of	 5	mm	was	 chosen,	 as	most	 of	 our	 clinically	 encountered	 displacements	 are	
on	the	order	of	5	mm.	In	this	case	only	dwell	positions	of	selected	catheters	were	translated	in	


























the	dose	 in	 the	bladder	decreased	 rapidly	 as	 a	 function	of	 a	 caudal	 implant	displacement.	 For	 all	
patients	the	V80	bladder	became	negligible	for	an	implant	displacement	of	3	mm	or	more.	Therefore,	
the effects	of	catheter	displacements	on	the	bladder	dose	were	not	analysed	in	more	detail.
The	 effect	 of	 displacement	 of	 selected	 catheter	 rows	 is	 evaluated	 for	 the	 case	 in	 which	 two	
neighbouring	 rows	 are	 displaced	 concurrently	 in	 order	 to	 predict	 critical	 factors.	 In	 figures	 3	
and	4,	 the	 location	of	the	two	displaced	rows	 is	depicted	on	the	X-axis.	On	the	 left,	the	clinical	
treatment	plan	 is	 shown,	 i.e.	 the	case	without	displacement	of	any	catheter	 rows.	From	 left	 to	
right	more	dorsal	towards	more	ventral	neighbouring	rows	of	catheter	rows	are	selected.	In	figure	


























Figure 5.2 | Effect	of	total	implant	displacement	on:	(A)	target	coverage,	(B)	V80	rectum	and	(C)	V120	urethra.





Target coverage (%) V80 bladder (cc) V80 rectum (cc) V120 urethra (cc)
Mean Range Mean Range Mean Range Mean Range
0* 95.0 93.9	–	95.9 0.66 0.24	–	1.35 0.6 0.4	–	0.7 0.02 0.01	–	0.03
3 91.4 90.5	–	92.4 0.02 0.00	–	0.04 1.1 0.8	–	1.3 0.03 0.01	–	0.05
5 87.2 86.1	–	87.9 0.00 0.00	–	0.00 1.5 0.9	–	1.8 0.06 0.01	–	0.10
7 82.6 81.5	–	83.1 0.00 0.00	–	0.00 1.8 1.0	–	2.2 0.10 0.02	–	0.18
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Figure 5.3 | The	target	coverage	(dashed	lines	relative	to	the	left	Y-axis)	as	a	function	of	a	5	mm	displacement	















on	 implantation	 technique	 but	 also	 varying	 along	 the	 treatment	 course.	 In	 general	 the	 largest	
displacements	occur	in	the	beginning	of	the	treatment	course.	Occasionally	a	single	patient	with	
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The	discussion	on	the	dosimetric	effects	due	to	implant	displacement	should	be	viewed	in	relation	
to	 other	 uncertainties	 in	HDR	brachytherapy,	 leading	 either	 to	 systematic	or	 random	errors	 in	








implants	because	of	 its	effects	on	 the	dosimetry,	are	much	smaller	 in	 temporary	HDR	prostate	
brachytherapy	due	to	the	short	time	course	3,23.	Another	source	of	inaccuracy	in	dosimetry	is	due	
to	the	inaccuracy	in	prostate	delineation.	CT	based	treatment	planning	for	prostate	brachytherapy	
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Fractionated HDR brachytherapy  
as monotherapy in prostate cancer:  
does implant displacement and its correction 
influence acute and late toxicity?










Chapter 6: Clinical influence of displacement correction in HDR-brachytherapy for prostate cancer
ABSTRACT






Methods and Materials:   
We	 analyzed	 162	 PCa	 patients	 treated	 with	 HDR-BT	 monotherapy	 between	 2007	 and	 2013.	




Results:   
Implant	 displacement	 corrections	 (DC)	 were	 needed	 in	 71	 patients	 (43.8%)	 whereas	 no	 
displacement	 corrections	 (NDC)	were	needed	 in	 91	patients	 (56.2%).	No	 statistically	 significant	
differences	were	seen	in	acute	and	late	grade	≥2	GU	and	GI	toxicity	incidences	between	DC	and	
NDC	 groups.	 The	maximum	displacement	 nor	 the	number	 of	 corrections	 had	 any	 influence	on	
toxicity.
Conclusions:   





Catheter	 displacements	 in	 high-dose-rate	 
brachytherapy	 (HDR-BT)	 for	 prostate	
cancer	 need	 to	 be	 corrected	 if	 exceeding	
3mm	to	ensure	accurate	dose	delivery.	The	
clinical	 effect	 of	 displacement	 correction	
on	 genitourinary	 and	 gastrointestinal	
toxicity	 incidences	 was	 evaluated	 in	 162	
patients	treated	with	HDR-BT.	No	significant	











High-dose-rate	 brachytherapy	 (HDR-BT)	 is	 a	 safe	 and	 effective	 treatment	 option	 for	 low-	 and	
intermediate-risk	 prostate	 cancer	 (PCa)	 and	 has	 been	 increasingly	 used	 as	 monotherapy	 1-3.	
From	a	dosimetric	point	of	view,	HDR-BT	is	an	ideal	technique	enabling	intensity	modulation	and	
individual	 adaptation	 of	 the	 dose,	 resulting	 in	 a	 highly	 conformal	 treatment	 with	 an	 excellent	






at	 risk	 (OAR).	Several	papers	have	addressed	catheter	displacement6-12.	All	 these	series	 showed	
that	displacement	of	 catheters	 (usually	occurring	 in	 caudal	direction)	needs	 to	be	 corrected	 to	







levels	and	that	no	effect	of	 the	corrected	displacements	on	toxicity	 incidences	 is	expected.	We	
























Sweden)	were	 implanted	 template-based	using	 transrectal	ultrasound	 imaging	with	 the	patient	
under	 spinal	 anaesthesia	 and	 in	 lithotomy	 position.	 Treatment	 planning	 was	 performed	 with	
















above	mentioned	 procedure	was	 repeated	 until	 the	 remaining	 displacement	was	within	 1mm	 to	





Data analysis  
All	patients	were	prospectively	followed	every	three	months	during	the	first	year,	and	twice	yearly	























The	 DC	 group	 was	 also	 stratified	 according	 to	 the	 maximum	 corrected	 displacement	 over	 all	
fractions	to	analyse	differences	in	toxicity.	Patients	with	maximum	displacement	corrections	up	to	
Table 6.1. | Patient	and	tumour	characteristics
n (%) Median (IQR)
Patients 162
Age	(yr) 68.9	(62.7-72.7)
Clinical T-stage T1c 110	(67.9%)
T2a 50	(30.9%)
T2b 2	(1.2%)
























patients	 (43.8%)	 one	 or	 more	 catheter	 displacement	 corrections	 (DC)	 were	 performed.	 In	 56	
(78.9%)	of	the	DC	patients	a	displacement	correction	before	one	of	the	four	fractions	was	done,	




Of	 all	 displacement	 corrections,	 3	 (3.4%)	were	 performed	 before	 fraction	 1,	 42	 (47.2%)	 before	
fraction	2,	28	(31.4%)	before	fraction	3	and	16	(18.0%)	before	fraction	4.




Table 6.2 | Number	of	patients	per	group
















for	 >3-5mm	 and	 >5mm	 corrections,	 respectively	 (p=0.119).	 In	 patients	 with	 one	 displacement	



































































































































































































































































































































































































































































































































































HDR-BT	 allows	 for	 a	 conformal	 high	 dose	 to	 the	 prostate	 by	 optimizing	 the	 source	 dwell	 times	
and	positions	in	the	implanted	catheters4.	However,	the	accuracy	of	dose	delivery	relies	on	dwell	
positions	being	accurately	reproduced	for	all	fractions	during	treatment.	In	clinical	practice,	caudal	
migration	 is	 often	 observed	 between	 fractions	 6-9.	 Hoskin	 et	 al.	 identified	 potential	 sources	 of	
catheter	displacement:	external	migration	of	the	catheters	through	the	skin,	 internal	movement	
of	 the	prostate	gland	and	edema	build-up	between	the	prostate	apex	and	perineum8.	Since	the	















et	 al.	 and	 Tiong	 et	 al.	 suggested	 to	 correct	 displacements	 exceeding	 3mm10,22.	 Other	 authors	
have	shown	with	simulation	studies	that	correcting	catheter	displacements	resulted	 in	restoring	
the target coverage to the planned level8,9,23.	As	the	same	is	true	for	OAR	dose,	one	could	expect	
that	toxicity	incidences	would	be	similar	for	the	DC	group	compared	to	the	NDC	group.	We	have	
implemented	 the	3mm	 limit	 for	 correction	 in	 our	 clinical	 protocol	 and	our	 results	 indicate	 that	
correction	of	catheter	displacements	above	this	limit	resulted	in	similar	toxicity	incidences	in	clinical	
practice.	Therefore,	catheter	displacement	is	no	longer	a	concern	once	checked	and	corrected.
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There	 are	 some	 uncertainties	 in	 the	 used	 method	 for	 determining	 and	 correcting	 catheter	




of	2.7	to	6.2%	or	absolute	changes	of	1.2	to	3.9cm3 were described for this period 7,12,19.	Marker	
distance	changes	that	were	reported	are,	therefore,	also	small.	Mean	absolute	changes	of	0.6	
to	3mm	were	 reported	 for	 the	36	hour	period	of	our	HDR-BT	 scheme	 12,19,24.	As	both	marker	
migration	and	prostate	volume	changes	are	small,	the	uncertainties	related	to	these	factors	in	
displacement	measurement	are	expected	to	be	limited.












































two	groups	with	 regard	 to	other	 factors	have	a	 larger	effect	on	 the	 toxicity	 incidences	 than	 the	
displacement	correction.
There	are	some	 limitations	of	 this	 study.	Firstly,	 the	 two	groups	 (NDC	vs.	DC)	were	prospectively	
followed	but	not	randomized.	However,	as	other	studies	have	shown	previously	that	displacements	
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CONCLUSION
The	 occurrence	 and	 subsequent	 correction	 of	 catheter	 displacements	 exceeding	 3mm	 before	
each	fraction	in	HDR-BT	as	monotherapy	for	PCa	did	not	lead	to	increased	acute	or	late	GU	and	
GI	toxicity	incidences.	The	maximum	displacement	and	the	number	of	displacement	corrections	
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Toxicity and quality of life after high-dose-rate 
brachytherapy as monotherapy for low- and 
intermediate-risk prostate cancer












Chapter 7: QoL and toxicity in HDR brachytherapy as monotherapy for prostate cancer
ABSTRACT 
Background and purpose
The	use	of	HDR	brachytherapy	 (HDR-BT)	as	monotherapy	 for	prostate	cancer	 (PC)	 is	 increasing	








Three	 months	 after	 treatment,	 acute	 GU	 and	 GI	 toxicities	 were	 reported	 in	 10.8%	 and	 7.2%.	
Acute	 toxicity	 resolved	within	 two	months	 in	 the	majority	of	patients	 (61%).	 Late	grade	≥2	GU	
and	GI	toxicity	were	reported	in	19.7%	and	3.3%	of	patients	12	months	after	HDR-BT.	Mean	QLQ-
PR25	scores	showed	clinically	 relevant	changes	 from	baseline	 for	urinary	symptoms	and	sexual	





























whereas	 patients	with	 PSA	 >10	 ng/ml,	 T2b	 and/or	 GS	 7,	 were	 defined	 as	 intermediate-risk	 PC	
(33%)15.	 The	 concomitant	 use	 of	 androgen	 deprivation	 therapy	 (ADT)	was	 not	 allowed.	 Patient	
characteristics	are	shown	in	Table	1.
Radiotherapy























Oncology	Group	 (RTOG)	 toxicity	 score	based	questionnaires	were	used	 to	 assess	 genitourinary	
(GU)	and	gastrointestinal	(GI)	toxicities17,18.	The	International	Prostate	Symptom	Score	(IPSS)	was	
used	to	evaluate	the	urinary	function	after	treatment.	QoL	was	assessed	by	the	prostate-specific	




Table 7.1 | Patient	and	tumour	characteristics




Clinical stage T1c 112	(67%)
T2a 52	(31%)
T2b 2	(1%)















Oncologic outcome and PSA












of	 treatment	on	urinary	 function	and	symptoms.	 In	 the	 IPSS	analysis,	 the	question	on	QoL	was	
left	out,	resulting	in	scores	ranging	from	0	to	35.	QLQ-PR25	scores	were	analysed	to	obtain	the	
net	 effect	 on	 QoL	 compared	 to	 baseline.	 Raw	 QLQ-PR25	 scores	 were	 linearly	 transformed	 to	
values	between	0	and	100,	where	higher	scores	reflect	more	symptoms	in	the	urinary	and	bowel	
symptoms	domain	or	higher	levels	of	sexual	functioning19.	For	all	domains	changes	of	≥10	points	
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Acute toxicity
The	 chronological	 incidences	 of	 grade	 ≥2	 GU	 and	 GI	 toxicities	 are	 depicted	 in	 Fig.	 1A	 and	 B,	
respectively.	The	incidence	of	grade	2	and	3	acute	GU	toxicity	was	19.3%	and	12.7%,	respectively.	
The	 incidence	 of	 grade	 2	 and	 3	 acute	 GI	 toxicity	 was	 21.7%	 and	 4.8%,	 respectively.	 Highest	
incidences	of	grade	2	and	3	acute	toxicity	were	reported	within	4	weeks	after	treatment.	Most	


















Table 7.2 | Variables	tested	in	univariate	logistic	regression	for	the	effect	on	acute	and	late	GU	and	GI	toxicity




















Quality of life assessment
Urinary	symptoms	score	of	 the	QLQ-PR25	 increased	>10	points	compared	to	baseline	 (clinically	
relevant)	during	the	first	three	years	after	treatment	(p<0.0001),	but	improved	thereafter.	Mean	
bowel	 symptoms	 score	 showed	 a	 slight	 increase	 compared	 to	 baseline.	 Although	 statistically	
significant	(p≤0.02),	the	mean	bowel	symptoms	QoL	score	increase	of	three	points	in	three	years	
was	not	clinically	relevant.	Mean	sexual	functioning	score	decreased	to	a	lowest	score	at	18	months	
FU	 and	 improved	 subsequently.	 Compared	 to	 baseline,	 the	 differences	 were	 both	 statistically	
significant	(p<0.0001)	and	clinically	relevant.	All	QLQ-PR25	scores	are	graphically	represented	in	
Fig.	3.	













































patients	 to	be	 treated	with	hypofractionated	 regimens.	Also,	 the	 found	 relation	between	good	
Qmax	of	>15	ml/s	with	the	lower	risk	of	acute	toxicity	is	important	for	patient	selection	to	limit	
acute	 toxicity.	 Incorporating	both	 these	 risk	 factors	 in	 the	 inclusion	criteria,	 could	 substantially	
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Quality of life assessment







Figure 7.3. | EORTC	QLQ-PR25	scores	on	urinary	symptoms	(A),	bowel	symptoms	(B)	and	sexual	functioning	















Sexual	 functioning	 can	 also	 be	 assessed	with	 the	 International	 Index	of	 Erectile	 Function	 (IIEF)	
questionnaire32,	which	will	provide	more	details	and	could	confirm	the	results	of	the	QLQ-PR25.




Besides	 the	absence	of	ADT,	we	used	one	 fractionation	schedule	 for	all	patients,	while	 in	most	





PSA	bounce	 is	a	known	phenomenon	 in	PC	patients	treated	with	radiotherapy	and	observed	 in	
20-40%	of	patients1,21,37,38.	The	results	of	this	study	are	in	line	with	those	in	literature.	We	used	the	
definition	of	Horwitz	where	an	increase	of	≥0.4	ng/ml	followed	by	any	decrease	was	considered	
a bounce21.	 In	 his	multi-institutional	 pooled	 data	 of	 4839	 patients,	 20%	 experienced	 a	 bounce	
according	 to	 this	 definition.	Most	 reports	 on	 bounce	 are	 from	 series	 in	 which	 ADT	was	 used.	
Reports	on	PSA	bounce	after	HDR-BT	monotherapy	 in	hormone-naïve	patients	are	 scarce.	 In	a	
cohort	 that	used	HDR-BT	monotherapy	 in	five	fractions	of	7-7.25	Gy,	PSA	bounce	was	reported	
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Sharper	selection	of	patients	to	these	extreme	hypofractionated	regimen	could	limit	toxicity	and	
improve	QoL.	 The	 rates	of	 acute	and	 late	 toxicity	 could	be	 limited	by	 sharpening	 the	 inclusion	
criteria	regarding	IPSS	score	and	Qmax	at	baseline.	
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Chapter 8: Early experience with SBRT as monotherapy for prostate cancer
ABSTRACT
Purpose































beam	 radiation	 therapy,	 interstitial	 brachytherapy	 (Low-Dose-Rate	 with	 Iodine	 seeds	 or	 High-
Dose-Rate),	hormonal	therapy,	watchful	waiting	and	active	surveillance2.	Drawbacks	of	external	
beam	radiation	are	the	normal	tissue	toxicity	and	the	 long	treatment	course	(8	weeks).	Several	



















In	 this	 report,	we	present	our	preliminary	 results	 in	a	prospectively,	well	documented	ongoing	
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Table 8.1. |	Inclusion	and	Exclusion	Criteria	

















but	 with	 less	 toxicity	 (by	 avoiding	 the	 mechanical	 damage	 due	 to	 needle	 insertion	 in	 HDR-
brachytherapy).	From	June	2008	through	June	2009	10	patients	underwent	HDR-like	Cyberknife	


































































toxicity	were	 graded	 using	 the	 RTOG	 scales19-20;	 both	 scales	 are	 summarized	multi-item	 scales.	
Computation	of	 the	QoL	scales	of	 the	questionnaires	 is	made	according	to	 the	 instructions;	 for	
missing	data	the	rule	of	half	is	used:	imputation	of	the	missing	items	with	the	mean	scale	score	is	
accepted	if	less	than	half	of	the	items	of	a	scale	are	missing.	






No. of patients (%)
 Radiation Therapy Oncology Group defecation symptoms
2 weeks 1	months 2	months 3	months 6	months
Mild 2/10	(20) 1/10	(10) 1/10	(10) 1/9	(11) 0/8	(0)
Moderate 1/10	(10) 0/10	(0) 0/10	(0) 0/9	(0) 0/8	(0)
Severe 0/10	(0) 0/10	(0) 0/10	(0) 0/9	(0) 0/8	(0)
 Radiation Therapy Oncology Group urinary symptoms
Mild 5/10	(50) 4/10	(40) 2/10	(20) 3/9	(33) 2/8	(25)
Moderate 2/10	(20) 2/10	(20) 2/10	(20) 1/9	(11) 1/8	(12)
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Patients Satisfaction
After	 the	 treatment	 each	 patient	 received	 a	 questionnaire	 about	 all	 steps	 of	 preparation	 and	










our	 experience	with	 the	 same	hypofractionated	 course	 (4	 x	 9.5	Gy)	 in	 the	HDR-brachytherapy	
setting,	we	noticed	that	the	Cyberknife	hypofractioanted	stereotactic	radiotherapy	course	caused	
even	 less	acute	urinary	toxicity	 21-23.	The	mechanical	 trauma	due	to	needle	 insertion	during	the	
HDR-brachythyerapy	may	well	explain	 the	difference	between	these	2	modalities	 (our	data	will	
be	 reported	 in	 the	 future).	Until	now	we	have	not	observed	any	severe	acute	urinary	or	 rectal	
toxicity	and	the	only	patient	that	needed	a	catheter	2	weeks	after	his	Cyberknife	treatment	was	




>15	were	excluded.	Fuller	et	al.	 reported	an	acceptable	acute	urinary	and	rectal	 toxicity	 for	his	
first	 10	 patients	 treated	with	 the	 Cyberknife	 following	 the	 same	 regimen	we	used	 (4	 fractions	
of	 9.5	 Gy)16.	 King	 et	 al.	 reported	 that	 patients	 treated	 with	 a	 hypofractionated	 stereotactic	
course	of	 radiotherapy	 for	 localized	prostate	 cancer	using	5	 fractions	of	7.25	Gy	had	 the	 same	
urinary	 and	 rectal	 toxicities	 as	 experienced	 with	 conventionally	 fractionated	 courses	 with	 an	
excellent	PSA	 response26.	 In	 their	data,	no	biochemical	 failure	was	 reported	after	a	median	FU	
of	33	months.	We	are	aware	 that	10	patients	 is	 a	 too	 small	population	and	 that	our	 follow-up	













external	 beam	 radiotherapy27, 28.	 The	 same	 response	 after	 hypofractionated	 regimen	 using	 the	
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Chapter 9: SBRT with focal boost to visible tumor for prostate cancer
ABSTRACT 
Background
There	 is	 growing	 evidence	 that	 prostate	 cancer	 (PC)	 cells	 are	 more	 sensitive	 to	 high	 fraction	
dose	 in	 hypofractionation	 schemes.	 High-dose-rate	 (HDR)	 brachytherapy	 as	 monotherapy	 is	
established	 to	 be	 a	 good	 treatment	 option	 for	 PC	 using	 extremely	 hypofractionated	 schemes.	






























(PC),	 the	 long	 course	 of	 7-9	weeks	 can	 have	 a	 negative	 impact	 on	 the	 patients’	 quality	 of	 life	















Between	 June	 2008	 and	November	 2011,	 50	 hormone-naïve	 patients	with	 biopsy-proven	 low-	
to	 intermediate-risk	 PC	 underwent	 SBRT	 treatment	 of	 PC,	 using	 the	 Cyberknife®, in four daily 
fractions	of	9.5	Gy	 to	a	 total	dose	of	38	Gy.	The	first	10	patients	were	 treated	 in	a	pilot	 study	
with the results reported in 20107.	The	inclusion	criteria	can	be	found	in	this	report	as	well.	These	
patients	were	not	eligible	for	HDR	brachytherapy	because	of	a	large	volume	of	the	prostate	(>	50	
cc),	or	a	combination	of	limited	urine	flow/second	(Q-max	<	10	ml/sec.)	and	a	significant	residual	




















can be found in an earlier report7.
PSA measurement, toxicity, and QoL












































n n% Mean (min.-max.)
  Age 68	(48-80)
  Fup (months) 23	(9-47)










Risk	Group Low risk 30 60%
Intermediate	risk 20 40%
Position	positive	biopsy Single sided 31 62%
Double sided 19 38%
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Late toxicity 









































Figure 9.2. | IPSS
International	Prostate	Symptoms	Score	(IPSS)	
changes	(mean)	
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Table 9.2. |	Toxicity	SBRT	published	series














































































































































































































































of	more	 than	30	minutes.	Although	 this	 subject	 requires	more	discussion	 it	may	play	 a	 role	 in	







difference	 in	measurement	 instrument	using	 the	EORTC/RTOG	criteria7, 15-17 in our group where 





The	 EORTC-QLQ	 PR-25	 questionnaire	 is	 a	 validated	 25-item	 instrument	 with	 four	 domains	
(urinary,	 bowel,	 sexual,	 and	 hormonal),	 as	 well	 as	 two	 urinary	 subscales	 of	 incontinence	 and	
irritative/bother23.	Responses	are	 transformed	 to	a	 scale	of	0-100.	For	 functional	 scales,	higher	
scores	 represent	 better	 QoL.	 For	 symptom	 scales,	 higher	 scores	 indicate	 more	 symptoms	 or	
more	problems. In	our	 cohort,	 there	was	a	 significant	 increase	 in	 the	urinary	 symptoms	 in	 the	
first	year	which	was	reversed	at	24	months.	The	bowel	symptoms	did	not	increase	and	remained	












Published	 results	of	SBRT	as	monotherapy	 reported	a	short	FU	and	many	variations	 in	 fraction	
size,	total	dose,	and	technique	used.	Also,	the	toxicity	was	measured	with	different	tools	making	
comparison	difficult.	The	group	of	Freeman	and	King	used	five	fractions	of	7-7.25	Gy	first	in	daily	
fractions	 but	 later	 in	 every-other-day	 fractions15, 16.	 They	 planned	 a	 more	 homogeneous	 dose	
distribution	and	used	less	strict	constraints.	This	is	 in	contrast	to	our	technique,	which	was	also	
used	by	Jabbari	21	administering	four	daily	fractions	of	9.5	Gy,	where	the	dose	distribution	inside	the	
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MODERATE HYPOFRACTIONATION: WHAT TO DO IN DAILY PRACTICE? 
Summary of published randomized phase III trials
Studies on the α/β	ratio	for	prostate	cancer,	based	on	different	radiotherapy	treatment	options,	
have	suggested	that	it	may	be	as	low	as	1.5	Gy8,10-13,15,18-20,22.	If	correct,	this	would	predict	an	enhanced	
therapeutic	 ratio	 for	 hypofractionated	 schedules	 compared	 to	 the	 currently	 applied	 standard	
schedules	using	1.8-2.0	Gy	daily	fractions.	To	date,	reports	are	available	of	six	phase	III	randomized	
studies	that	have	investigated	moderate	hypofractionation59,61-64.	Two	trials	were	executed	prior	
to the era of dose escalated radiotherapy29,30.	Lukka	et	al.64	reported	results	of	936	patients	with	
low-	and	 intermediate-risk	prostate	cancer	 in	a	non-inferiority	phase	 III	hypofractionation	 trial,	

































policy.	 The	 hypothesized	 increase	 in	 bRFS	 was	 not	 observed:	 76.7%	 vs.	 78.6%	 for	 standard	
fractionation	(p=0.74).	There	were	no	differences	in	late	toxicity.








of	 life	outcome	was	 similar	 in	all	 arms65.	Recently,	 the	5-year	efficacy	and	 toxicity	 results	were	
presented,	showing	non-inferiority	of	60	Gy	regimens,	with	comparable	late	toxicity	rates66.




















treatment	 times,	 and	 different	 toxicity	 scores.	 It	 also	 included	 different	 numbers	 of	 patients	 and	
reported	different	follow-up	(FU)	periods.	The	policy	on	the	use	of	HT	was	always	different.	All	these	
factors	should	be	carefully	taken	into	consideration	when	comparing	results	from	various	series59,67,70,71.	
Evidence for increased treatment efficacy with hypofractionation













Only	 the	 randomized	 trial	 by	 Pollack	 et	 al.59	 and	 the	 HYPRO	 trial26 hypothesized superiority 





















Recently,	 an	 enhanced	 biological	 efficacy	 of	 delivered	 radiation	 dose	 with	 reduced	 overall	
treatment	 time	 (OTT)	 of	 0.3	 Gy/day	 of	 treatment	 time	 reduction	 was	 reported	 for	 prostate	
cancer73.	 In	 the	 randomized	 trials	 by	 Arcangeli	 et	 al.70,	 Pollack	 et	 al.59,	 and	 Dearnaley	 et	 al.62, 
OTT	was	2.8-4	weeks	 shorter	 in	 the	hypofractionation	arm,	which	would	 suggest	an	enhanced	
advantage	for	hypofractionation	by	decreasing	the	OTT.	In	the	study	by	Arcangeli	et	al.61 this could 
have	contributed	to	the	observed	gain	in	bRFS	in	the	hypofractionation	arm.	However,	Pollack	et	
al.	did	not	observe	 the	expected	superiority	of	hypofractionation.	Also	 in	 the	HYPRO	trial,	OTT	





indicates	 the	need	 for	 caution	when	applying	 these	 schedules	 to	avoid	enhanced	 complication	
rates	for	patients.









fractionation.	 The	 hypothesized	 reduced	 late	 rectal	 toxicity	 was	 not	 observed.	 In	 the	 study	 by	




















no	 indication	 that	 the	 variability	would	be	different	 for	hypofractionation	 compared	 to	 standard	
deviation.	Therefore,	it	is	to	be	expected	that	delineation	uncertainty	will	not	impact	the	conclusion	
that	the	rectum	α/β	ratio	is	probably	considerably	lower	than	5	Gy.


















results	 robust.	The	reported	7-years	bRFS	of	97%	is	excellent	even	for	 low-	and	 intermediate-risk	









Increasing	 belief	 in	 a	 low	 α/β	 ratio	 for	 prostate	 cancer	 encouraged	 the	 use	 of	 HDR-BT	 as	
monotherapy.	 The	 rapid	 fall-off	 of	 the	 dose	 towards	 the	 rectum	 and	 bladder	may	 explain	 the	
low	 toxicity	 reported	 after	 HDR-BT.	 Compared	 to	 EBRT	 series,	 our	 5	 year	 report	 on	 HDR-BT	
monotherapy	 showed	 relatively	 low	 toxicity,	 despite	 toxicity	 registration	 using	 both	 physician	
reports	 and	 PSAQ77,81.	 The	 investigated	 QoL	 using	 the	 EORTC-QLQ	 PR25	 questionaires42 gave 




























































































toxicity	 rates	were	 very	 acceptable	 and	 comparable	with	 other	 series.	 However,	 the	 number	 of	
patients	in	all	above	mentioned	single	institutional	series	was	small	with	relatively	short	FU.











Quality of Life studies
As	the	majority	of	patients	treated	with	SBRT	is	low-risk	with	an	excellent	bRFS	and	long	survival,	it	
is	particularly	important	to	also	investigate	quality	of	life	(QoL).	Unfortunately	QoL	data	for	prostate	




after	around	6	months.	The	sexual	 function	declined	 in	the	first	9	months	after	treatment.	 In	our	
QoL	 report	 (Chapter	 9)	 the	QLQ-PR25	 questionnaires	were	 used,	which	were	 comparable	 to	 the	
above	mentioned	EPIC	scores.	The	patterns	of	recovery	were	comparable	to	the	results	of	the	pooled	




Although	 thousands	 of	 prostate	 cancer	 patients	 have	 been	 treated	 with	 profound	 SBRT	
hypofractionation,	there	are	as	yet	no	randomized	studies	that	have	compared	this	approach	with	
standard	fractionation.	In	the	UK,	an	on-going	randomized	trial	is	investigating	this	approach99.










were	not	observed,	posing	questions	on	 the	widely	assumed	 low	α/β-ratio	 for	prostate	cancer.	
In the CHHiP trial66,	the	expected	non-inferiority	of	hypofractionation	was	indeed	demonstrated,	
however,	 applied	 tumor	 doses	were	 possibly	 on	 the	 low	 side,	 especially	 for	 high-risk	 patients.	
Compared	 to	 the	 study	 by	 Pollack	 et	 al.59	 and	 the	 CHHiP	 trial,	 the	 fraction	dose	 in	 the	HYPRO	
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prostate	 cancer.	 In	 recent	 years	 there	has	been	a	 lot	of	 attention	 for	hypofractionated	 (daily	
dose	>	 2	Gy)	 radiotherapy	 in	prostate	 cancer,	mainly	due	 to	 the	 assumed	 low	α/β	 ratio	 that	
determines	the	sensitivity	of	prostate	cancer	cells	for	hypofractionated	radiotherapy.	
The	 purpose	 of	 this	 thesis	 was	 to	 investigate	 the	 feasibility	 of	 moderate	 and	 extreme	
hypofractionated	 radiotherapy	 for	 prostate	 cancer	 with	 emphasis	 on	 treatment	 induced	
morbidity,	 scored	 by	 both	 treating	 physicians	 and	 patients	 using	 patient	 self-assessment	














incidence	 of	 grade	 ≥2	 acute	 GI	 toxicity	 was	 higher	 for	 HF	 (42%	 vs.	 31.2%,	 p=0·0015).	 Three	
months	after	completion	of	 treatment,	 there	was	no	difference	between	the	arms	 in	grade	≥	
2	acute	GI	toxicity.	The	use	of	the	PSAQ	on	top	of	physician	scoring	largely	increased	reported	
toxicity	incidences.
In	 Chapter	 3,	we	 report	 on	 the	 late	 toxicity	 in	 the	HYPRO	 trial,	 including	 387	 SF	 and	 395	HF	


















In	 Chapter	 6,	we	 reported	 on	 the	 consequences	 of	 performing	 corrections	 in	 case	 of	 catheter	































een	 belangrijke	 behandeloptie.	 De	 mogelijkheden	 zijn:	 uitwendige	 bestraling	 (‘external	 beam	
radiotherapy’,	EBRT)	en	inwendige	bestraling	(brachytherapie),	waarbij	zowel	een	laag	dosistempo	
(‘low	dose	rate’,	 LDR)	als	een	hoog	dosistempo	 (‘high	dose	rate’,	HDR)	gebruikt	kan	worden.	 In	
de	afgelopen	jaren	is	er	veel	aandacht	geweest	voor	het	hypofractioneren	van	de	bestraling	van	
prostaatkanker,	wat	voornamelijk	samenhangt	met	de	veronderstelde	lage	α/β	ratio.
Het	doel	 van	dit	 proefschrift	was	het	onderzoeken	van	de	haalbaarheid	 van	matig	en	extreem	
hypogefractioneerde	 radiotherapie	 voor	 prostaatkanker.	 Hierbij	 werd	 vooral	 gekeken	 naar	 de	
bijwerkingen	 (toxiciteit)	 van	 de	 behandeling,	 zoals	 die	werden	 gescoord	 door	 de	 behandelend	
artsen	 en	 door	 de	 patiënten	 zelf,	 middels	 gevalideerde	 vragenlijsten	 (‘patient	 self-assessment	
quesionnaires’,	 PSAQ).	 Matig	 hypogefractioneerde	 bestralingen	 werden	 uitgevoerd	 met	 een	
conventionele	versneller	(Hoofdstukken	2	en	3),	terwijl	extreem	hypogefractioneerde	bestralingen	
werden	 uitgevoerd	 met	 HDR	 brachytherapie	 (Hoofdstukken	 4-7),	 of	 een	 robotversneller,	 de	
Cyberknife	(Hoofdstukken	8	en	9).
In	de	hoofdstukken	2	en	3	worden	de	acute	en	 late	urogenitale	 en	 gastro-intestinale	 toxiciteit	
van	 de	 bestraling	 gerapporteerd,	 zoals	 waargenomen	 in	 de	 nationale	 HYPRO	 studie.	 In	 deze	
gerandomiseerde	 fase	 III	 studie	 werden	 patiënten	 met	 matig-	 of	 hoog-risico	 prostaatkanker	
willekeurig	 ingedeeld	voor	behandeling	met	de	standaard	 fractionering	 (SF)	van	39	 fracties	van	
2	Gy	 in	8	weken	of	de	hypogefractioneerde	 (HF)	behandeling	van	19	 fracties	van	3.4	Gy	 in	6½ 
week.	 Patiënten	werden	 gestratificeerd	naar	 deelnemend	 centrum	en	 risicogroep.	 Ten	 aanzien	
van	toxiciteit	waren	de	primaire	eindpunten	van	deze	studie	de	non-inferioriteit	van	HF	voor	de	
cumulatieve	incidentie	van	graad	≥	2	acute	en	late	urogenitale	en	gastro-intestinale	bijwerkingen.
In	 hoofdstuk	 2	 wordt	 gerapporteerd	 over	 de	 acute	 toxiciteit	 in	 de	 HYPRO	 studie	 voor	 391	 en	
403	patiënten	die	respectievelijk	behandeld	zijn	met	SF	en	HF.	De	analyses	zijn	gebaseerd	op	4	
meetmomenten	per	patiënt:	voorafgaand	aan	de	behandeling,	twee	keer	tijdens	de	behandeling	



















resulteerde	 het	 toevoegen	 van	 de	 PSAQ	 in	 substantiële	 verhogingen	 van	 de	 gerapporteerde	
toxiciteit	incidenties.
In	hoofdstuk	4	worden	de	 toxiciteit	en	 lange-termijn	uitkomsten	beschreven	voor	264	 laag-	en	 
matig-risico	 prostaatkankerpatiënten	 die	 behandeld	 zijn	 met	 een	 HDR	 boost	 van	 3x6	 Gy,	
gecombineerd	met	25	fracties	EBRT	van	1.8	Gy.	Zelfs	met	de	gecombineerde	toxiciteitsscore	van	

























hypogefractioneerde	 bestralingen	 met	 de	 Cyberknife	 robotversneller.	 Uitgangspunt	 was	 een	
bestraling	 met	 4	 dagelijkse	 fracties	 van	 9.5	 Gy,	 afgegeven	 met	 een	 dosisverdeling	 die	 HDR	






(3	 patiënten	 hadden	 graad	 2	 urogenitale	 toxiciteit	 en	 2	 hadden	 graad	 1-2	 gastro-intestinale	
toxiciteit)	en	vergelijkbaar	met	andere	bestralingsopties.
In	 hoofdstuk	 9	 worden	 de	 toxiciteit	 en	 QoL	 beschreven	 voor	 50	 laag-	 en	 matig-risico	
prostaatkankerpatiënten	die	behandeld	werden	met	de	Cyberknife	met	4	dagelijkse	fracties	van	
9.5	Gy.	Met	een	mediane	follow-up	van	2	jaar	was	de	recidiefvrije	overleving	100%.	De	IPSS	score	






































Brachytherapie-collegae,	 dr.	 Praag	 en	 dr.	 Jansen.	 Beste	 John	 en	 Peter,	 hartelijk	 dank	 voor	 de	
enorme	inzet	van	jullie	voor	de	brachytherapie;	patiënten	includeren,	 lang	in	de	FU	houden,	en	
uitgebreid	overleggen	en	feedback	geven	over	wat	in	dit	boek	is	beschreven	over	brachytherapie.
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Hypofractionated radiotherapy for prostate cancer:  
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